BioNTech SE (NASDAQ:BNTX - Free Report) - HC Wainwright boosted their Q3 2024 EPS estimates for BioNTech in a report released on Tuesday, August 27th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.86 for the quarter, up from their prior forecast of $0.85. HC Wainwright currently has a "Buy" rating and a $113.00 price target on the stock. The consensus estimate for BioNTech's current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech's Q4 2024 earnings at $0.63 EPS, Q3 2025 earnings at $0.83 EPS and Q4 2025 earnings at $0.80 EPS.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company's revenue was down 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.86) EPS.
A number of other equities research analysts also recently weighed in on BNTX. HSBC raised shares of BioNTech from a "hold" rating to a "buy" rating in a research note on Friday, August 2nd. BMO Capital Markets cut their price target on BioNTech from $123.00 to $122.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 7th. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. Evercore ISI initiated coverage on BioNTech in a research note on Tuesday, May 14th. They issued an "inline" rating and a $100.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded BioNTech from a "hold" rating to a "buy" rating and set a $95.00 target price for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $109.09.
Read Our Latest Research Report on BNTX
BioNTech Trading Up 1.3 %
NASDAQ:BNTX traded up $1.09 on Wednesday, hitting $88.20. 442,802 shares of the stock were exchanged, compared to its average volume of 696,346. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a 52 week low of $76.53 and a 52 week high of $125.83. The stock has a market capitalization of $20.97 billion, a price-to-earnings ratio of 174.22 and a beta of 0.23. The company's 50-day moving average price is $83.88 and its 200 day moving average price is $89.40.
Institutional Investors Weigh In On BioNTech
A number of hedge funds and other institutional investors have recently bought and sold shares of BNTX. CWM LLC grew its stake in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company's stock worth $26,000 after acquiring an additional 217 shares in the last quarter. GAMMA Investing LLC increased its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after buying an additional 150 shares during the last quarter. Frazier Financial Advisors LLC bought a new stake in BioNTech during the 4th quarter worth about $30,000. First Horizon Advisors Inc. acquired a new position in shares of BioNTech during the 4th quarter worth about $38,000. Finally, Covestor Ltd boosted its stake in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
